Serum levels of fibroblast growth factor 2 in children with orthopedic diseases: Potential role in predicting bone healing

Journal of Orthopaedic Research

Volumn 31, Issue 2, 2013, Pages 249-256

  Granchi, Donatella ^a   Devescovi, Valentina ^a   Pratelli, Loredana ^a   Verri, Elisabetta ^a   Magnani, Marina ^a   Donzelli, Onofrio ^a   Baldini, Nicola ^a,b  

^a RIZZOLI ORTHOPAEDIC INSTITUTE   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

bone lesion; bone repair; fibroblast growth factor 2; mineralization; serum marker

Indexed keywords

FIBROBLAST GROWTH FACTOR 2;

ADOLESCENT; ADULT; ARTICLE; BONE DISEASE; BONE LESION; BONE MARROW; BONE MINERALIZATION; CHILD; CONGENITAL PSEUDARTHROSIS; DIAGNOSTIC ACCURACY; FEMALE; FRACTURE; FRACTURE HEALING; HUMAN; IN VITRO STUDY; INFANT; MAJOR CLINICAL STUDY; MALE; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; STROMA CELL; TREATMENT OUTCOME;

ADOLESCENT; BONE REMODELING; CALCIFICATION, PHYSIOLOGIC; CHILD; CHILD, PRESCHOOL; FEMALE; FIBROBLAST GROWTH FACTOR 2; FRACTURES, BONE; HUMANS; INFANT; MALE; PSEUDARTHROSIS;

EID: 84871611087     PISSN: 07360266     EISSN: 1554527X     Source Type: Journal    
DOI: 10.1002/jor.22219     Document Type: Article

References (41)

1. Shrader MW, Stans AA, Shaughnessy WJ, et al. 2009. Nonunion of fractures in pediatric patients: 15-year experience at a level I trauma center. Orthopedics 32: 410-415.
2. Wilkins KE,. 2005. Principles of fracture remodeling in children. Injury 36: A3-A11.
3. Arslan H, Subasà M, Kesemenli C, et al. 2002. Occurrence and treatment of nonunion in long bone fractures in children. Arch Orthop Trauma Surg 122: 494-498.
4. Lindaman LM,. 2001. Bone healing in children. Clin Podiatr Med Surg 18: 97-108.
5. Baldini N, Cenni E, Ciapetti G, et al. 2009. Bone repair and regeneration. In:, Planell JA, editor. Bone repair biomaterials. Cambridge: Woodhead Publishing Limited, p 69-118.
6. Jingushi S, Heydemann A, Kana SK, et al. 1990. Acidic fibroblast growth factor (aFGF) injection stimulates cartilage enlargement and inhibits cartilage gene expression in rat fracture healing. J Orthop Res 8: 364-371.
7. Itoh N, Ornitz DM,. 2011. Fibroblast growth factors: from molecular evolution to roles in development, metabolism and disease. J Biochem 149: 121-130.
8. Yun YR, Won JE, Jeon E, et al. 2010. Fibroblast growth factors: biology, function, and application for tissue regeneration. J Tissue Eng 2010: 218142.
9. Zhang X, Sobue T, Hurley MM,. 2002. FGF-2 increases colony formation, PTH receptor, and IGF-1 mRNA in mouse marrow stromal cells. Biochem Biophys Res Commun 290: 526-531.
10. Xiao G, Jiang D, Gopolakrishnan R, et al. 2002. Fibroblast growth factor 2 induction of the osteocalcin gene requires MAPK activity and phosphorylation of the osteoblast transcription factor, Cbfa1/Runx2. J Biol Chem 277: 36181-36187.
11. Pitaru S, Kotev-Emeth S, Noff D, et al. 1993. Effect of basic fibroblast growth factor on the growth and differentiation of adult stromal bone marrow cells: enhanced development of mineralized bone-like tissue in culture. J Bone Miner Res 8: 919-929.
12. Marie PJ,. 2003. Fibroblast growth factor signaling controlling osteoblast differentiation. Gene 316: 23-32.
13. Mansukhani A, Bellosta P, Sahni M, et al. 2000. Signaling by fibroblast growth factors (FGF) and fibroblast growth factor receptor 2 (FGFR2)-activating mutations blocks mineralization and induces apoptosis in osteoblasts. J Cell Biol 149: 1297-1308.
14. Chikazu D, Hakeda Y, Ogata N, et al. 2000. Fibroblast growth factor (FGF)-2 directly stimulates mature osteoclast function through activation of FGF receptor 1 and p42 MAP kinase. J Biol Chem 275: 31444-31450.
15. Collin-Osdoby P, Rothe L, Bekker S, et al. 2002. Basic fibroblast growth factor stimulates osteoclast recruitment, development, and bone pit resoption in association with angiogenesis in vivo on the chick chorioallantoic membrane and activates isolated avian osteoclast resorption in vitro. J Bone Miner Res 17: 1859-1871.
16. Montero A, Okada Y, Tomita M, et al. 2000. Disruption of the fibroblast growth factor-2 gene results in decreased bone mass and bone formation. J Clin Invest 105: 1085-1089.
17. Xiao L, Sobue T, Esliger A, et al. 2010. Disruption of the Fgf2 gene activates the adipogenic and suppresses the osteogenic program in mesenchymal marrow stromal stem cells. Bone 47: 360-370.
18. Weiss S, Zimmermann G, Pufe T, et al. 2009. The systemic angiogenic response during bone healing. Arch Orthop Trauma Surg 129: 989-997.
19. D'Amore PA, Brown RH Jr, Ku PT, et al. 1994. Elevated basic fibroblast growth factor in the serum of patients with Duchenne muscular dystrophy. Ann Neurol 35: 362-365.
20. Yetgin S, Yenicesu I, Cetin M, et al. 2001. Clinical importance of serum vascular endothelial and basic fibroblast growth factors in children with acute lymphoblastic leukemia. Leuk Lymphoma 42: 83-88.
21. Kobayashi H, Miyakita H, Yamataka A, et al. 2004. Serum basic fibroblast growth factor as a marker of reflux nephropathy. J Pediatr Surg 39: 1853-1855.
22. Honsawek S, Chongsrisawat V, Vejchapipat PI, et al. 2008. High levels of serum basic fibroblast growth factor in children with biliary atresia. Hepatogastroenterology 55: 1184-1188.
23. Granchi D, Devescovi V, BaglÃo SR, et al. 2010. Biological basis for the use of autologous bone marrow stromal cells in the treatment of congenital pseudarthrosis of the tibia. Bone 46: 780-788.
24. Bossuyt PM, Reitsma JB, Bruns DE, et al. 2003. Towards complete and accurate reporting of studies of diagnostic accuracy: the STARD initiative. BMJ 326: 41-44.
25. Deeks JJ,. 2001. Systematic reviews in health care: systematic reviews of evaluations of diagnostic and screening tests. BMJ 323: 157-162.
26. Larsson A, Sköldenberg E, Ericson H,. 2002. Serum and plasma levels of FGF-2 and VEGF in healthy blood donors. Angiogenesis 5: 107-110.
27. Malamitsi-Puchner A, Tziotis J, Tsonou A, et al. 2000. Basic fibroblast growth factor: serum levels in the female. Growth Factors 17: 215-220.
28. Sundaram K, Senn J, Yuvaraj S, et al. 2009. FGF-2 stimulation of RANK ligand expression in Paget's disease of bone. Mol Endocrinol 23: 1445-1454.
29. Kurtz A, Martuza RL,. 2002. Antiangiogenesis in neurofibromatosis 1. J Child Neurol 17: 578-584.
30. Kawachi Y, Xu X, Ichikawa E, et al. 2003. Expression of angiogenic factors in neurofibromas. Exp Dermatol 12: 412-417.
31. Mashour GA, Ratner N, Khan GA, et al. 2001. The angiogenic factor midkine is aberrantly expressed in NF1-deficient Schwann cells and is a mitogen for neurofibroma-derived cells. Oncogene 20: 97-105.
32. Cancedda R, Bianchi G, Derubeis A, et al. 2003. Cell therapy for bone disease: a review of current status. Stem Cells 21: 610-619.
33. Coipeau P, Rosset P, Langonne A, et al. 2009. Impaired differentiation potential of human trabecular bone mesenchymal stromal cells from elderly patients. Cytotherapy 11: 584-594.
34. Chen WJ, Jingushi S, Anzai J, et al. 2004. Effects of FGF-2 on metaphyseal fracture repair in rabbit tibiae. J Bone Miner Metab 22: 303-309.
35. Radomsky ML, Aufdemorte TB, Swain LD, et al. 1999. A novel formulation of FGF-2 in a hyaluronan gel accelerates fracture healing in non-human primates. J Orthop Res 17: 607-614.
36. Kawaguchi H, Jingushi S, Izumi T, et al. 2007. Local application of recombinant human fibroblast growth factor-2 on bone repair: a dose-escalation prospective trial on patients with osteotomy. J Orthop Res 25: 480-487.
37. Kawaguchi H, Oka H, Jingushi S, et al. 2010. A local application of recombinant human fibroblast growth factor 2 for tibial shaft fractures: a randomized, placebo-controlled trial. J Bone Miner Res 25: 2735-2743.
38. Gerstenfeld LC, Cullinane DM, Barnes GL, et al. 2003. Fracture healing as a post-natal developmental process: molecular, spatial, and temporal aspects of its regulation. J Cell Biochem 88: 873-884.
39. Sarahrudi K, Thomas A, Mousavi M, et al. 2011. Elevated transforming growth factor-beta 1 (TGF-β1) levels in human fracture healing. Injury 42: 833-837.
40. Anitua E, SÃnchez M, Nurden AT, et al. 2006. New insights into and novel applications for platelet-rich fibrin therapies. Trends Biotechnol 24: 227-234.
41. Cenni E, Savarino L, Perut F, et al. 2010. Background and rationale of platelet gel in orthopedic surgery. Musculoskelet Surg 94: 1-8.